Published in ISRN Gastroenterol on July 29, 2012
Two-week triple therapy has a higher Helicobacter pylori eradication rate than 1-week therapy: A single-center randomized study. Saudi J Gastroenterol (2015) 1.01
Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study. BMC Gastroenterol (2013) 1.00
Choosing optimal first-line Helicobacter pylori therapy: a view from a region with high rates of antibiotic resistance. Curr Pharm Des (2014) 0.93
Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a prospective randomized study. Eur J Clin Pharmacol (2013) 0.84
Antibiotic treatment for Helicobacter pylori: Is the end coming? World J Gastrointest Pharmacol Ther (2015) 0.80
Mechanisms of gastroprotection of methanol extract of Melastoma malabathricum leaves. BMC Complement Altern Med (2015) 0.78
High antibiotic resistance rate: A difficult issue for Helicobacter pylori eradication treatment. World J Gastroenterol (2015) 0.77
Real-Time PCR detection and quantitation of Helicobacter pylori clarithromycin-resistant strains in archival material and correlation with Sydney classification. Ann Gastroenterol (2013) 0.75
Increasing gastric juice pH level prior to anti-Helicobacter pylori therapy may be beneficial to the healing of duodenal ulcers. Exp Ther Med (2013) 0.75
Helicobacter pylori infection. N Engl J Med (2002) 14.81
Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut (2006) 9.03
American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol (2007) 7.49
Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med (2007) 5.62
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet (2011) 5.21
Clinical practice. Helicobacter pylori infection. N Engl J Med (2010) 4.94
Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut (2010) 4.43
Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev (2000) 4.03
Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med (2008) 3.72
Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther (2007) 3.53
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol (2009) 3.18
Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter (2010) 2.50
Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis (2010) 2.40
Comparison of biopsy sites for the histopathologic diagnosis of Helicobacter pylori: a topographic study of H. pylori density and distribution. Gastrointest Endosc (1994) 2.36
A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol (2011) 2.35
The importance of efflux pumps in bacterial antibiotic resistance. J Antimicrob Chemother (2003) 2.12
The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol (2006) 2.09
Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol (2011) 1.98
Evidence-based guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr (2011) 1.95
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol (2006) 1.83
Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis (2011) 1.80
A new look at anti-Helicobacter pylori therapy. World J Gastroenterol (2011) 1.59
The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen. Aliment Pharmacol Ther (1999) 1.59
Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther (2004) 1.53
Is antimicrobial susceptibility testing necessary before first-line treatment for Helicobacter pylori infection? Meta-analysis of randomized controlled trials. Intern Med (2010) 1.51
Evaluation of treatment regimens to cure Helicobacter pylori infection--a meta-analysis. Aliment Pharmacol Ther (1999) 1.45
Pharmacologic aspects of eradication therapy for Helicobacter pylori Infection. Gastroenterol Clin North Am (2010) 1.26
Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand J Gastroenterol (2001) 1.25
Geographic map and evolution of primary Helicobacter pylori resistance to antibacterial agents. Expert Rev Anti Infect Ther (2010) 1.22
Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment Pharmacol Ther (2011) 1.22
Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther (2010) 1.21
Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days? Helicobacter (2011) 1.21
Increasing the duration of dual amoxicillin plus omeprazole Helicobacter pylori eradication to 6 weeks: a pilot study. J Gastroenterol Hepatol (2012) 1.20
Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. Am J Gastroenterol (2000) 1.18
Helicobacter pylori and antibiotic resistance. Gut (2007) 1.17
Latin-American Consensus Conference on Helicobacter pylori infection. Latin-American National Gastroenterological Societies affiliated with the Inter-American Association of Gastroenterology (AIGE). Am J Gastroenterol (2000) 1.17
Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study). Arch Intern Med (2002) 1.16
Prevalence of primary fluoroquinolone resistance among clinical isolates of Helicobacter pylori at a University Hospital in Southern Taiwan. Helicobacter (2009) 1.16
The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter (2002) 1.10
Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: a pilot study. Helicobacter (2008) 1.10
Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy. Int J Antimicrob Agents (2002) 1.09
Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a meta-analysis. J Clin Pharm Ther (2009) 1.08
The eradication of Helicobacter pylori is affected by body mass index (BMI). Obes Surg (2008) 1.07
Evolution of Helicobacter pylori therapy from a meta-analytical perspective. Helicobacter (2007) 1.07
Gastric infection by Helicobacter pylori. Curr Gastroenterol Rep (2011) 1.06
Is Helicobacter pylori a cause of gastric cancer? An appraisal of the seroepidemiological evidence. Cancer Epidemiol Biomarkers Prev (1994) 1.05
Treatment of Helicobacter pylori. Curr Opin Gastroenterol (2011) 1.03
Extragastric manifestations of Helicobacter pylori infection. Helicobacter (2011) 1.02
Treatment options for patients with Helicobacter pylori infection resistant to one or more eradication attempts. Dig Liver Dis (2003) 1.01
The changing epidemiology of GERD: geography and Helicobacter pylori. Am J Gastroenterol (2003) 0.99
cagA Status and eradication treatment outcome of anti-Helicobacter pylori triple therapies in patients with nonulcer dyspepsia. J Clin Microbiol (2001) 0.98
Treatment of Helicobacter pylori infection 2011. Helicobacter (2011) 0.97
Helicobacter pylori and gastroesophageal reflux disease: a case-control study. Helicobacter (2008) 0.97
Helicobacter pylori and gastric cancer. Recent Results Cancer Res (2011) 0.96
Helicobacter pylori and nonmalignant diseases. Helicobacter (2011) 0.96
Effect of smoking and histological gastritis severity on the rate of H. pylori eradication with omeprazole, amoxicillin, and clarithromycin. Helicobacter (1999) 0.96
Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection. Clin Gastroenterol Hepatol (2005) 0.96
Helicobacter pylori infection and nonmalignant diseases. Helicobacter (2010) 0.94
H. pylori treatment: new wine in old bottles? Am J Gastroenterol (2009) 0.93
A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole. Aliment Pharmacol Ther (2001) 0.93
Improving compliance with helicobacter pylori eradication therapy: when and how? Therap Adv Gastroenterol (2009) 0.91
Genome-wide germline analyses on cancer susceptibility and GeMDBJ database: Gastric cancer as an example. Cancer Sci (2010) 0.90
Triple vs quadruple therapy for treating Helicobacter pylori infection: an updated meta-analysis. Aliment Pharmacol Ther (2003) 0.89
Systematic review: the effect of Helicobacter pylori and its eradication on gastro-oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis. Aliment Pharmacol Ther (2004) 0.88
Clinical aspects of gastric cancer and Helicobacter pylori--screening, prevention, and treatment. Helicobacter (2010) 0.87
A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter (2003) 0.87
Effects of Helicobacter pylori eradication on gastroesophageal reflux disease. Helicobacter (2011) 0.86
A prospective study of a one-week nonbismuth quadruple therapy for childhood Helicobacter pylori infection. J Pediatr Surg (2001) 0.84
GastroPanel: evaluation of the usefulness in the diagnosis of gastro-duodenal mucosal alterations in children. Clin Chim Acta (2008) 0.83
Sequential treatment for Helicobacter pylori eradication in children. Gut (2008) 0.82
Helicobacter pylori therapy in children: overview and challenges. Int J Immunopathol Pharmacol (2010) 0.82
Gastric wash-based molecular testing for antibiotic resistance in Helicobacter pylori. Digestion (2011) 0.78
Will H. pylori stagger under the weight of this LOAD? A novel but expensive eradication regimen. Am J Gastroenterol (2011) 0.77
Maintenance of Helicobacter pylori eradication rates with triple therapy over 12 years in a Spanish hospital. Helicobacter (2012) 0.77
Seeking an optimal eradication therapy for Helicobacter pylori infection. J Gastroenterol Hepatol (2012) 0.76
The coeliac iceberg in Italy. A multicentre antigliadin antibodies screening for coeliac disease in school-age subjects. Acta Paediatr Suppl (1996) 2.18
Anti-ganglioside antibodies in children with coeliac disease: correlation with gluten-free diet and neurological complications. Aliment Pharmacol Ther (2004) 2.18
Prevalence and clinical picture of celiac disease in italian down syndrome patients: a multicenter study. J Pediatr Gastroenterol Nutr (2001) 1.19
Role of anti-transglutaminase (anti-tTG), anti-gliadin, and anti-endomysium serum antibodies in diagnosing celiac disease: a comparison of four different commercial kits for anti-tTG determination. J Clin Lab Anal (2001) 1.13
Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment Pharmacol Ther (2003) 0.96
Polymorphism of the IRGM gene might predispose to fistulizing behavior in Crohn's disease. Am J Gastroenterol (2009) 0.95
Inflammatory bowel disease in children and adolescents in Italy: data from the pediatric national IBD register (1996-2003). Inflamm Bowel Dis (2008) 0.92
Transient pseudohypoaldosteronism in obstructive renal disease with transient reduction of lymphocytic aldosterone receptors. Results in two affected infants. Horm Res (1993) 0.90
Reflux oesophagitis in children; the role of endoscopy. A multicentric Italian survey. Dig Liver Dis (2007) 0.86
Schönlein-Henoch vasculitis and chronic Helicobacter pylori associated gastritis and duodenal ulcer: a case report. Pediatr Med Chir (1998) 0.84
Transcriptional downregulation of tight junction protein ZO-1 in active coeliac disease is reversed after a gluten-free diet. Dig Liver Dis (2004) 0.83
Successful unrelated bone marrow transplantation for Shwachman-Diamond syndrome. Bone Marrow Transplant (2001) 0.80
Role of CARD15, DLG5 and OCTN genes polymorphisms in children with inflammatory bowel diseases. World J Gastroenterol (2007) 0.79
Focal nodular hyperplasia of the liver associated with portal vein agenesis: a morphological and immunohistochemical study of one case and review of the literature. Adv Clin Path (1999) 0.78
Coeliac disease associated with peripheral neuropathy in a child: a case report. Neuropediatrics (1998) 0.78
Effect of cagA status on the sensitivity of enzyme immunoassay in diagnosing Helicobacter pylori-infected children. Helicobacter (1999) 0.76
[High prevalence of hepatitis C virus infection in patients with non-Hodgkin's lymphoma at the onset. Preliminary results of an Italian multicenter study]. Recenti Prog Med (1998) 0.76
Autism and esophageal achalasia in childhood: a possible correlation? Report on three cases. Dis Esophagus (2012) 0.75
The importance of acoustic impedance measurements in middle ear pathology during acute viral respiratory illness in the first year of life. Int J Pediatr Otorhinolaryngol (1981) 0.75
[Non-organic failure to thrive: retrospective study in hospitalized children]. Pediatr Med Chir (1997) 0.75
Transient erythoblastopenia in coeliac disease. Haematologica (2001) 0.75
Insights in the laboratory diagnosis of celiac disease. Lupus (2006) 0.75
The antiphospholipid syndrome and infections in a child with trisomy 21. Autoimmun Rev (2008) 0.75
Protein-losing enteropathy after fontan operation: treatment with elementary diet in one case. Pediatr Cardiol (2000) 0.75
[Purulent pericarditis in one infant (author's transl)]. Pediatr Med Chir (1982) 0.75
[Abdominal pain syndrome recurring after 40 years: critical revision]. Pediatr Med Chir (1996) 0.75
Experience of recurrent abdominal pain: evaluation based on the Eland scale. J Pain Symptom Manage (1997) 0.75
Exhaled nitric oxide and hepatopulmonary syndrome in a 6-year-old child. Pediatrics (1999) 0.75
Pediatric liver transplantation: the University of Padua experience. Transplant Proc (2007) 0.75